Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Shares Up 0.3% – Still a Buy?

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR)’s stock price shot up 0.3% on Monday . The company traded as high as $25.80 and last traded at $25.80. Approximately 980 shares changed hands during trading, a decline of 54% from the average daily volume of 2,122 shares. The stock had previously closed at $25.72.

Amplify Weight Loss Drug & Treatment ETF Stock Up 0.3%

The firm’s 50-day moving average price is $24.97 and its 200-day moving average price is $25.16. The company has a market cap of $5.16 million, a P/E ratio of 24.31 and a beta of 0.37.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC grew its stake in shares of Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) by 5.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 24,891 shares of the company’s stock after acquiring an additional 1,215 shares during the period. Jane Street Group LLC owned 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 at the end of the most recent reporting period.

Amplify Weight Loss Drug & Treatment ETF Company Profile

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.